TABLE 1.
Experimental design of control and treatment protocols for PRRSV and S. suis coinfection
| Group | No. of pigs | Challengea | Treatment (codeb) | Dose | Routec | Day(s) of treatment |
|---|---|---|---|---|---|---|
| 1 | 11 | None | None (NC) | |||
| 2 | 11 | PRRS and S. suis | None (PC) | |||
| 3 | 11 | PRRS and S. suis | Procaine penicillin G (Pfi-Pen G) (PEN) | 66,000 IU/kg | i.m. | 8, 9, 10 |
| 4 | 11 | PRRS and S. suis | Tiamulin (Denagard) (TIA) | 23.1 mg/kg | p.o. | 8, 9, 10 |
| 5 | 11 | PRRS and S. suis | Ceftiofur (Excenel) (CEF) | 5.0 mg/kg | i.m. | 8, 9, 10 |
| 6 | 10 | PRRS and S. suis | Autogenous S. suis vaccine (SS VX) | 2 ml | i.m. | −18, −4 |
| 7 | 11 | PRRS and S. suis | MLV PRRSV vaccine (RespPRRS/Repro) (PR VX) | 2 ml | i.m. | −14 |
a
PRRSV challenge on day 0, S. suis challenge on day 7.
b
NC, negative controls; PC, positive controls; PEN, penicillin; TIA, tiamulin; CEF, ceftiofur; SS VX, S. suis vaccine; PR VX, PRRSV vaccine.
c
i.m., intramuscular injection; p.o., per os via drinking water.